Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades PLx Pharma to Perform

Oppenheimer Downgrades PLx Pharma to Perform

Oppenheimer analyst Leland Gershell downgrades PLx Pharma (NASDAQ:PLXP) from Outperform to Perform.

byBenzinga Newsdesk

August 15, 2022

1 minute read

Oppenheimer analyst Leland Gershell downgrades PLx Pharma (NASDAQ:PLXP) from Outperform to Perform.

Eversource’s Q4 Earnings Miss, Offshore Wind Business Exit, Eyes Water Distribution Business Sale & More

By Lekha Gupta

February 14, 7:15 AM

Eversource Energy reported Q4 FY23 revenue of $2.69B, missing consensus of $3.24B. Adjusted earnings rose to $333.5M but adjusted EPS of $0.95 missed consensus. FY24 adjusted EPS outlook is $4.50-$4.67.

Morgan Stanley Maintains Equal-Weight on Visteon, Raises Price Target to $115

By Benzinga Newsdesk

October 28, 11:40 AM

Morgan Stanley analyst Adam Jonas maintains Visteon (NASDAQ:VC) with a Equal-Weight and raises the price target from $107 to $115.

Analyst Ratings

Analyst Ratings for Gap

By Benzinga Insights

November 7, 2:00 PM

Analysts have provided the following ratings for Gap (NYSE:GPS) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

GPS

News
Tech

Forget Self-Driving: Nio’s ET9 Is Snow-Defying, Thanks To Its Innovative Chassis System

By Anan Ashraf

February 20, 3:09 AM

ET9's by-wire controlled car chassis, Nio says, delivers an experience similar to cruising in a business jet.

NIO

Oppenheimer Downgrades PLx Pharma to Perform

Related Posts

Eversource’s Q4 Earnings Miss, Offshore Wind Business Exit, Eyes Water Distribution Business Sale & More

Morgan Stanley Maintains Equal-Weight on Visteon, Raises Price Target to $115

Analyst Ratings for Gap

Forget Self-Driving: Nio’s ET9 Is Snow-Defying, Thanks To Its Innovative Chassis System